The Increasing Incidence Of PAH In the World Is Driving the Growth of the Global Pulmonary Arterial Hypertension Drug Market
Pulmonary Arterial Hypertension Drug Market |
Pulmonary
Arterial Hypertension Drug Market, by Drug Class
(Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5)
Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue,
Calcium Channel Blockers, Others), by Route of Administration (Oral, Inhaled,
Intravenous, Subcutaneous), by Distribution Channel (Hospital Pharmacies,
Retail Pharmacies, and Online Pharmacies), and by Region (North America,
Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share,
Outlook, and Opportunity Analysis, 2022 - 2030.
The
global Pulmonary Arterial Hypertension Drug Market is estimated to be valued at
US$ 7,310.1 Million in 2022 and is expected to reach US$ 11,220.2 million by
2030, at a CAGR of 5.5% during the forecast period (2022–2030).
Market
Overview:
Pulmonary
Arterial Hypertension (PAH) is a progressive and potentially
life-threatening condition that affects the pulmonary arteries, which are the
blood vessels that carry blood from the heart to the lungs. In PAH, the small
arteries in the lungs become narrowed, blocked, or damaged, leading to
increased resistance to blood flow through the lungs.
PAH is classified as a
subgroup of a broader condition called pulmonary hypertension (PH), which
includes various types of high blood pressure in the pulmonary arteries. However,
PAH specifically refers to pulmonary hypertension that occurs when the cause is
unknown or due to certain genetic or hereditary factors.
Competitive
Landscape:
Major players operating
in the global Pulmonary Arterial Hypertension
Drug Market include Mylan N.V., Sun Pharmaceutical
Industries Ltd., Sandoz AG, Daiichi Sankyo Company, Limited, Arena
Pharmaceuticals, Actelion Pharmaceuticals Ltd, Gilead Sciences, Inc., Pfizer
Inc., Merck KGaA, Bayer AG, AstraZeneca, Novartis AG, GlaxoSmithKline plc., and
United Therapeutics Corporation.
Key
Market Drivers:
The prevalence of PAH
is rising globally due to factors such as changing lifestyles, sedentary
habits, and aging populations. The growing prevalence of risk factors like
obesity and cardiovascular diseases has contributed to the increasing incidence
of Pulmonary Arterial Hypertension Drug
Market. This is expected to augment the growth of the global pulmonary
arterial hypertension drug market. For instance, according to the National
Institutes of Health (NIH), annually 93 cases per million individuals are
diagnosed with pulmonary arterial hypertension.
Significant
advancements in drug development have been witnessed in the PAH market. Several
new therapies, including prostacyclin analogs, endothelin receptor antagonists,
and phosphodiesterase-5 inhibitors, have been introduced, offering improved
treatment options for patients. The development of combination therapies and
targeted therapies is estimated to enhance the growth of the global pulmonary
arterial hypertension drug market.
Increasing healthcare
expenditure, particularly in emerging economies, has positively influenced the
global pulmonary arterial hypertension drug market. Growing healthcare
infrastructure, rising disposable incomes, and government initiatives to
improve healthcare access have led to increased spending on PAH treatment,
driving market growth.
Covid-19
Impact Analysis:
The pandemic raised
awareness about respiratory health, resulting in an increased focus on
conditions like PAH. This awareness is expected to boost the growth of the
global pulmonary arterial hypertension drug market, as governments and
healthcare organizations prioritize the management of pulmonary diseases. For
instance, in July 2022, Cereno Scientific stated that the first individuals had
been included in the Phase II study for CS1, which is a PAH drug candidate.
Key
Takeaways:
·
North America is expected to dominate
the growth of the global pulmonary arterial hypertension drug market. Factors
such as the high prevalence of PAH, well-established healthcare infrastructure,
and early adoption of advanced therapies contribute to the region's market
growth. Additionally, the presence of key market players and extensive research
activities further drive the market in North America. For instance, in June
2022, Gossamer Bio, Inc. published the preclinical information supporting the
efficiency of seralutinib, which can be used for treating PAH.
·
The Asia Pacific region is estimated to
witness high growth in the global pulmonary arterial hypertension drug market,
owing to factors such as a large population, increasing disposable incomes, and
improving healthcare infrastructure. Rising awareness, the launch of generic
drugs, and the presence of a vast untapped market contribute to the region's
growth potential. For instance, according to Janssen Australia, more than 2000
individuals are in Australia.
Comments
Post a Comment